M.D., Chief Medical Officer of Valneva, commented, “This latest approval is a further recognition of IXCHIQ®’s strong product profile and the medical need for a chikungunya vaccine.

M.D., Chief Medical Officer of Valneva, commented, “This latest approval is a further recognition of IXCHIQ ® ’s strong product profile and the medical need for a chikungunya vaccine.

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years and older, but Bavarian Nordic’s Vimkunya is the first chikungunya vaccine ...

VALNEVA Declaration of shares and voting ... for the world’s first and only chikungunya vaccine, IXCHIQ®. The single-dose vaccine is indicated for active immunization for the prevention of ...

Valneva's Ixchiq vaccine – which was cleared in the EU, the US, and Canada last year – is currently indicated for preventing chikungunya disease in adults only, although, it is in clinical ...

Valneva has bolstered its vaccines pipeline ... its COVID-19 jab and recent approval for the world's first chikungunya vaccine Ixchiq – is paying €10 million upfront for a stake in ...

Vaccine specialist Valneva has picked up an approval from the MHRA, as well. The agency approved the company's chikungunya vaccine, Ixchiq, for use in people 18 years of age and older. Late-stage ...

Factbox-Pending US Vaccine Decisions as Kennedy Takes Top Health Job (Reuters) - Robert F. Kennedy Jr, a vaccine critic who has pledged to tackle chronic disease, was confirmed by the U.S. Senate ...

SC Weaver is an inventor on a UTMB patent application describing IRES-attenuated alphavirus vaccines ... in the production of this manuscript. Chikungunya virus (CHIKV) causes an acute febrile ...